SCHEMBL13633799

SCHEMBL13633799

CCO[C@H](CNC(=O)OC(C)(C)C)Cc1ccc(OCCc2nc(-c3ccccc3)oc2C)cc1

nearest known ligand 0.62

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARG P37231 19/20 0.62
PPARA Q07869 13/20 0.62
PPARD Q03181 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4027916 0.89 PPARG (0.69) PPARGPPARAPPARD
SCHEMBL4027235 0.86 PPARG (0.64) PPARGPPARAPPARD
SCHEMBL4028468 0.84 FFAR1 (0.60) PPARGPPARAPPARD
SCHEMBL13721247 0.84 PPARG (0.63) PPARGPPARAPPARD
SCHEMBL6203537 0.83 PPARG (0.67) PPARGPPARAPPARD
SCHEMBL4027819 0.83 PPARG (0.65) PPARGPPARAPPARD
SCHEMBL4026297 0.82 PPARG (0.55) PPARGPPARAPPARD
SCHEMBL4030015 0.82 FFAR1 (0.58) PPARGPPARA
SCHEMBL4032154 0.82 PPARG (0.64) PPARGPPARAPPARD
SCHEMBL7914288 0.82 PPARG (0.68) PPARGPPARAPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed
EP-1569916-B1 SUBSTITUTED ARALKYL DERIVATIVES CADILA HEALTHCARE LTD (IN) 2009-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275565-A1 Substituted aralkyl derivatives UGT1A7, UGT1A10, UGT2B7 PPARG 2043/4885PPARA 2339/4885PPARD 1965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.